- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

Spectrum Solutions’ offerings enhanced by including CLIA/CAP laboratory testing, custom assay development, and manufacturing of industry-leading microarray chip technology. These valuable assets, ...